newsfilter
← Latest News
GlobeNewswire·

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel,